Praxis Precision Medicines and Tenacia Biotechnology Have Entered Into a Licensing and Collaboration Agreement for Ulixacaltamide in the Greater China Region

Praxis Precision Medicines, Inc has entered into an exclusive collaboration and license agreement with Tenacia Biotechnology (Shanghai) Company, Ltd., a clinical-stage biopharmaceutical company in China focusing on central nervous system (CNS) drug development. The collaboration aims to develop and commercialize ulixacaltamide for the treatment of essential tremor in Greater China, covering mainland China, Hong Kong, Macau, and Taiwan.

Praxis President and CEO, Marcio Souza, highlighted the significance of the collaboration in addressing the unmet needs of essential tremor patients in China. The partnership with Tenacia, known for its expertise in CNS treatments, is anticipated to contribute to the advancement of ulixacaltamide innovation.

Tenacia CEO Xiaoxiang Chen emphasized the public health impact of essential tremor in China, affecting millions of people with limited therapeutic options. Ulixacaltamide is seen as a promising and innovative solution for this condition, and the collaboration with Praxis is a strategic move to bring this treatment to patients in Greater China.

Under the agreement, Praxis will receive an upfront payment of $15 million, including $5 million in cash and a $10 million investment in Praxis common stock. Additional milestone payments of up to $264 million, tied to development, regulatory, and commercialization achievements, will be made. Praxis will also be entitled to tiered royalties on net sales.

Praxis' legal counsel was provided by Sidley Austin LLP, while Ropes & Gray LLP served as legal counsel to Tenacia.

Ulixacaltamide, a selective small molecule inhibitor targeting T-type calcium channels, aims to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit associated with tremor activity. It represents the most advanced program within Praxis' Cerebrum™ small molecule platform and is currently in development for essential tremor treatment.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!